Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 194.285 USD 0.27% Market Closed
Market Cap: 55.7B USD

Becton Dickinson and Co
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Becton Dickinson and Co
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Becton Dickinson and Co
NYSE:BDX
Accounts Receivables
$3B
CAGR 3-Years
11%
CAGR 5-Years
5%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
Accounts Receivables
$2.8B
CAGR 3-Years
15%
CAGR 5-Years
12%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Accounts Receivables
$3.6B
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Accounts Receivables
$8.1B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
9%
IDEXX Laboratories Inc
NASDAQ:IDXX
Accounts Receivables
$638.8m
CAGR 3-Years
14%
CAGR 5-Years
12%
CAGR 10-Years
13%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Receivables
$1.3B
CAGR 3-Years
14%
CAGR 5-Years
16%
CAGR 10-Years
14%
No Stocks Found

Becton Dickinson and Co
Glance View

Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.

BDX Intrinsic Value
273.524 USD
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Becton Dickinson and Co's Accounts Receivables?
Accounts Receivables
3B USD

Based on the financial report for Sep 30, 2025, Becton Dickinson and Co's Accounts Receivables amounts to 3B USD.

What is Becton Dickinson and Co's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
6%

Over the last year, the Accounts Receivables growth was -1%. The average annual Accounts Receivables growth rates for Becton Dickinson and Co have been 11% over the past three years , 5% over the past five years , and 6% over the past ten years .

Back to Top